Clinical resourceProfessional clinical guidance
- Source type
- Clinical resource
- Access type
- Publisher
- Publisher
- Pfizer Hospital US
- Date
- 2026-07
- Added
- 2026-07-05
Trust profile
VV Source Trust Matrix v1.0
VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.
82
Professional clinical guidance
- Publisher type
- Professional guidance
- Bias profile
- Moderate
This source is strongest for safety and consumer context and weaker for mechanism and trial discovery.
VV Source Fit Score 1.0
Fit by use case
Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.
- Regulatory status
- 63/100
- Context Source
- Clinical outcomes
- 78/100
- Strong Support
- Mechanism
- 63/100
- Context Source
- Safety
- 86/100
- Strong Support
- Consumer context
- 82/100
- Strong Support
- Trial discovery
- 63/100
- Context Source
Best used for
- Clinical context
- Practice guidance
Weak for
- Replacing primary evidence
Used in Viral Vitalism
Backgroundbrief1 reference
FDA Extended the Only U.S.-Licensed Coral Snake Antivenin Lot
Roles: Background
Related studies
No structured study record is currently attached to this source.
Related sources
Regulatory labelU.S. health regulator
DailyMed: North American coral snake antivenin label
Regulatory-label context for North American coral snake antivenin.
- Trust score
- 94
- Publisher
- DailyMed / National Library of Medicine
- Access
- Official
- Usage
- 1 connection
GovernmentU.S. health regulator
FDA: North American coral snake antivenin expiration-date extension
Primary FDA safety and availability source for coral snake antivenin Lot CL6814 extension.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 1 connection
Topic tags
coral-snakeantiveninsnakebiteemergency-medicinepfizerdrug-supply